A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
The study was done to:
- test a strategy of using a resistance test to choose anti-HIV drugs
- see how well combinations of new anti-HIV drugs work to lower HIV infection
- see if taking new anti-HIV drugs together is safe and tolerable
- see if text messages improve people's anti-HIV drug-taking behavior (only at sites
participating in the adherence study)
- in people taking certain combinations of anti-HIV drugs with an anti-TB drug, compare
how these drugs act in the body
- to see how people do after they stop having frequent clinic visits as part of a research
study
Phase:
Phase 4
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborators:
AbbVie Dimagi Inc. Gilead Sciences Janssen Pharmaceuticals Merck Sharp & Dohme Corp. National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Darunavir Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Etravirine HIV Protease Inhibitors Protease Inhibitors Raltegravir Potassium Tenofovir